KIT and bladder transitional cell carcinoma: The driver genes ERBB2, HDAC1, PARP1, ERBB3, FGFR3, mTOR, AXL, EZH2, FGFR1, FGFR2, CSF1R, KIT, FGFR4, RET, and ERBB4 are key targets in the treatment of BLCA.